Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus

See also
Status	Clinical Trial	Phase
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Recruiting	`NCT05967520` - JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus	Phase 2
Completed	`NCT02875691` - Effect of Green Tea on Treatment of Lupus	Phase 2
Completed	`NCT02922114` - Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients	N/A
Withdrawn	`NCT01702038` - Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE	Phase 2
Terminated	`NCT00368264` - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )	Phase 2/Phase 3
Completed	`NCT00094380` - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)	Phase 1/Phase 2
Completed	`NCT00065806` - Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)	Phase 3
Completed	`NCT00005436` - Lupus Cohort--Thrombotic Events and Coronary Artery Disease	N/A
Recruiting	`NCT03543839` - Trial of Belimumab in Early Lupus	Phase 4
Completed	`NCT03098823` - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE	Phase 4
Recruiting	`NCT05899907` - Efficacy and Safety of Telitacicept in Early SLE	Phase 4
Completed	`NCT04956484` - Belimumab In Early Systemic Lupus Erythematosus	Phase 4
Completed	`NCT05326841` - Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .	Phase 3
Completed	`NCT02655640` - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis	N/A
Completed	`NCT02034344` - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers	Phase 0
Terminated	`NCT00089804` - Study of LJP 394 in Lupus Patients With History of Renal Disease	Phase 3
Completed	`NCT00071487` - Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)	Phase 2
Completed	`NCT02349061` - A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus	Phase 2
Recruiting	`NCT05636670` - Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease

NCT number	NCT03427151
Study type	Interventional
Source	ImmuPharma
Contact
Status	Completed
Phase	Phase 3
Start date	February 27, 2018
Completion date	February 5, 2019

Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus — IP-006

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms